drugset
drugset / Trial / NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497 ↗

Phase 3 Recruiting 850 enrolled Bristol-Myers Squibb BioNTech SE · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Timeline

Start
2026-03-16
Primary completion
2030-09-18
Completion
2033-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Durvalumab Monoclonal antibody — —
Subject Pumitamig Protein / enzyme biologic — —

Indications

non-small cell lung carcinoma